UNION is a clinical-stage, diversified pharmaceutical company focused on identifying, developing and commercializing treatments for immunology and infectious diseases. Our current portfolio is comprised of two medicinal compound classes with established modes of action that hold significant potential to address underserved medical needs. UNION is based in Greater Copenhagen, Denmark.


UNION was incorporated in 2011 as AntibioTx, initially focusing on infectious diseases and in particular the growing and serious issue of antimicrobial resistance (AMR).

In advanced screenings of well-characterized compounds, the company’s scientists identified several compounds with potential outside known indications, including niclosamide.

During the work with the anti-bacterial properties of niclosamide, the team also discovered novel anti-inflammatory properties. This led to expansion of the disease focus to also include immunology with the starting point in immune-dermatology. Because of the expanded therapeutic focus, the company was renamed to UNION therapeutics A/S in 2018.

In March 2020, researchers at the Pasteur Institute in Seoul screened a large number of molecules for activity against SARS-CoV-2. Niclosamide was identified to have a 40-fold higher potency in vitro against SARS-CoV-2 than remdesivir. UNION researchers managed to develop a high concentration solution of niclosamide, which could be combined with both nasal spray pumps and nebulizers supporting sufficient delivery to the target organs involved in COVID-19. 

Following successful Phase I study of niclosamide in COVID-19, intranasal niclosamide (UNI91103) was selected to the UK platform trial PROTECT-V in autumn 2020, testing the prophylactic effect of niclosamide in immune compromised kidney and vasculitis patients. UNION therapeutics is currently also preparing studies with intranasal niclosamide in people tested positive for COVID-19 who are either asymptomatic of only elicit mild symptoms to investigate the efficacy of niclosamide to stop disease progression and shorten time with disease.

In June 2020, UNION therapeutics acquired the full Phosphodiesterase 4 (PDE4) inhibitor program from LEO Pharma. The lead candidate, orismilast, has been selected as a next generation PDE4 inhibitor, with high selectivity for PDE4 subtypes particularly involved in immunologic disease. Orismilast is available both as a tablet and as a topical cream. The tablet of orismilast has been investigated in patients with moderate to severe psoriasis and delivered a robust proof of concept. Orismilast cream has been investigated in patients with mild-severe atopic dermatitis and also in this indication delivered a robust proof of concept. The broad immunomodulating effects of orismilast supports pursuit of further indications for which underserved medical needs exist.


Learn more